ESR1 and neoplasm: Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive tumours, both have a particularly poor prognosis, with higher rates of recurrence when compared to hormone ER (estrogen receptor) and PR (progesterone receptor) positive cases [2].